{"name":"sigma-tau i.f.r. S.p.A.","slug":"sigma-tau-i-f-r-s-p-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Eurartesim","genericName":"Eurartesim","slug":"eurartesim","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Eurartesim dispersible oral tablet","genericName":"Eurartesim dispersible oral tablet","slug":"eurartesim-dispersible-oral-tablet","indication":"Uncomplicated Plasmodium falciparum malaria","status":"phase_2"}]}],"pipeline":[{"name":"Eurartesim","genericName":"Eurartesim","slug":"eurartesim","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Eurartesim dispersible oral tablet","genericName":"Eurartesim dispersible oral tablet","slug":"eurartesim-dispersible-oral-tablet","phase":"phase_2","mechanism":"Eurartesim is a fixed-dose combination of dihydroartemisinin and piperaquine, targeting the hemozoin formation in Plasmodium parasites to treat malaria.","indications":["Uncomplicated Plasmodium falciparum malaria"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}